ELI LILLY & CO (LLY.DE) Stock Price, Quote, News and Overview
FRA:LLY - Deutsche Boerse Ag - US5324571083 - Common Stock - Currency: EUR
LLY.DE Quote, Performance and Key Statistics
FRA:LLY (3/7/2025, 7:00:00 PM)
801.7
-51.6 (-6.05%)
The current stock price of LLY.DE is 801.7 EUR. In the past month the price decreased by -5.63%. In the past year, price increased by 14.77%.
LLY.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
| ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
| JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
| NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
| SNW.DE | SANOFI | 14.32 | 275.64B | ||
| SAN.PA | SANOFI | 14.27 | 274.84B | ||
| 1SAN.MI | SANOFI | 14.19 | 273.18B | ||
| 6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
| 1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
| PFE.DE | PFIZER INC | 8.69 | 140.81B | ||
| 1PFE.MI | PFIZER INC | 8.6 | 139.42B |
Related stock screener links
About LLY.DE
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. The company is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 43000
Company Website: https://www.lilly.com/
Investor Relations: https://investor.lilly.com/
Phone: 13172762000
ELI LILLY & CO / LLY.DE FAQ
What is the stock price of ELI LILLY & CO today?
The current stock price of LLY.DE is 801.7 EUR. The price decreased by -6.05% in the last trading session.
What is the ticker symbol for ELI LILLY & CO stock?
The exchange symbol of ELI LILLY & CO is LLY and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is LLY.DE stock listed?
LLY.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for ELI LILLY & CO stock?
32 analysts have analysed LLY.DE and the average price target is 955.16 EUR. This implies a price increase of 19.14% is expected in the next year compared to the current price of 801.7. Check the ELI LILLY & CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELI LILLY & CO worth?
ELI LILLY & CO (LLY.DE) has a market capitalization of 760.15B EUR. This makes LLY.DE a Mega Cap stock.
How many employees does ELI LILLY & CO have?
ELI LILLY & CO (LLY.DE) currently has 43000 employees.
What are the support and resistance levels for ELI LILLY & CO (LLY.DE) stock?
ELI LILLY & CO (LLY.DE) has a support level at 748.01 and a resistance level at 844.83. Check the full technical report for a detailed analysis of LLY.DE support and resistance levels.
Is ELI LILLY & CO (LLY.DE) expected to grow?
The Revenue of ELI LILLY & CO (LLY.DE) is expected to grow by 31.45% in the next year. Check the estimates tab for more information on the LLY.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ELI LILLY & CO (LLY.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LLY.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LLY.DE, evaluating the profitability, health, valuation and growth aspects
- ELI LILLY & CO (LLY.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELI LILLY & CO (LLY.DE) Sales and EPS estimates to see what analysts future expectations are.
- ELI LILLY & CO (LLY.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELI LILLY & CO (LLY.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELI LILLY & CO (LLY.DE) Stock Chart to make your own analysis
- ELI LILLY & CO (LLY.DE) Latest news and press-releases to stay up to date.
Does ELI LILLY & CO (LLY.DE) stock pay dividends?
ELI LILLY & CO (LLY.DE) has a dividend yield of 0.66%. The yearly dividend amount is currently 4.55. Check the full fundamental report for a detailed analysis of LLY.DE dividend history, reliability and sustainability.
When does ELI LILLY & CO (LLY.DE) report earnings?
ELI LILLY & CO (LLY.DE) will report earnings on 2025-05-01, before the market open.
What is the Price/Earnings (PE) ratio of ELI LILLY & CO (LLY.DE)?
The PE ratio for ELI LILLY & CO (LLY.DE) is 66.98. This is based on the reported non-GAAP earnings per share of 11.97 and the current share price of 801.7 EUR. Check the full fundamental report for a full analysis of the valuation metrics for LLY.DE.
LLY.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to LLY.DE. When comparing the yearly performance of all stocks, LLY.DE is one of the better performing stocks in the market, outperforming 72.08% of all stocks.
LLY.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to LLY.DE. While LLY.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.
LLY.DE Financial Highlights
Over the last trailing twelve months LLY.DE reported a non-GAAP Earnings per Share(EPS) of 11.97. The EPS increased by 105.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.51% | ||
| ROA | 13.45% | ||
| ROE | 74.62% | ||
| Debt/Equity | 2.01 |
LLY.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to LLY.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 79.4% and a revenue growth 31.45% for LLY.DE